Poster – Automated Segmentation of MS Brain Lesions

Cortechs.ai was pleased to have this UC San Diego School of Medicine poster presented at ACTRIMS Forum 2018

Automated quantitative measures from MRI, such as lesion volume and distribution, have significant value for clinicians evaluating disease progression. Clinical standards for lesion evaluation include visual inspection of MRI images, or expert manual segmentation of lesions. These subjective measurements lack standardization and reproducibility in clinical settings

Cortechs.ai’ LesionQuant module is a fully-automated lesion segmentation tool for clinical use designed to provide accurate and reproducible lesion segmentations. This study demonstrates that automated segmentation of MS lesion volumes and counts by LesionQuant provides reproducible results that correlate well with expert manual counts and analysis.

For more information about LesionQuant or this poster, contact us. Click image below to view in pdf.

Cortechs.ai | Poster – Automated Segmentation of MS Brain Lesions

More Resources

09/18/2026

What a Head CT Can and Can’t Tell You About a Concussion

For Concussion Awareness Day, learn how quantitative CT analysis can help measure subtle structural changes and support follow-up after traumatic brain injury.

09/09/2026

Prostate Cancer Awareness Month: Finding the Cancer That Matters

How quantitative MRI can bring greater clarity to decisions across the prostate cancer journey.

09/01/2026

Quantifying What Matters: Advancing Alzheimer’s Imaging with NeuroQuant®

Explore how quantitative imaging is transforming Alzheimer’s care, from structural volumetrics and amyloid PET to treatment monitoring with NeuroQuant®.

08/19/2026

Brain Metastases Imaging Insights from SNO/ASCO 2026

Explore key insights from SNO/ASCO 2026 on brain metastases imaging, including lesion tracking, volumetric analysis, SRS workflows, and automated segmentation.

08/18/2026

Cortechs.ai Announces FDA Clearance for NeuroQuant® PET: Advancing Molecular Imaging for Cognitive Impairment

NeuroQuant® PET receives FDA 510(k) clearance, advancing quantitative PET imaging for cognitive impairment.

08/04/2026

Cortechs.ai Expands European CE Marking Across AI Imaging Platform, Accelerating Global Growth

Cortechs.ai expands EU CE Marking for the latest NeuroQuant®, NeuroQuant® Brain Tumor, and OnQ™ Prostate, advancing global AI imaging innovation
Scroll to Top